HIV/AIDS Studies
Conclusion: Fulvic acids may help treat HIV infection.
Title: Treatment of HIV infection with humic acids.
Document Type: Patent
Conclusion: A large number of studies show that humic extracts, specifically fulvic acids, effectively and safely kill the HIV/AIDS virus. A pharmaceutical company has patented a humic-based drug that purifies blood for transfusions and kills the HIV virus without harming blood cells.
Link: https://patents.google.com/patent/US20040137085A1/en
____________________________________________________________
Conclusion: Humic substances show antiviral properties against HIV-1.
Title: Antiviral activity of natural humic substances and shilajit materials against HIV-1: relationship with structure
Document Type: Peer-Reviewed Journal Article
Conclusion: It was concluded that typical humic materials and Shilajit differ greatly in their molecular composition, and that humic materials have substantial preferences as a natural source of antiviral agents compared to shilajit.
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554000/
____________________________________________________________
Conclusion: Shilajit reduces HIV resistance to antiretroviral therapy.
Title: Clinical evaluation of Shilajatu Rasayana in patients with HIV infection
Document Type: Peer-Reviewed Journal Article
Conclusion: The results show that Shilajatu (mineral pitch or Shilajit) decreases recurrent HIV virus resistance to ART and improves therapy outcome.
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215318/
________________________________________________________
Conclusion: Humic acid interferes with HIV multiplication.
Title: Natural humic substances interfere with multiple stages of the human immunodeficiency virus replication cycle
Document type: Conference summary
Conclusion: The results showed that humic acid (HA) and himatomelanic acid (HMA) fractions exhibited distinct antiviral activity within the concentration range of 0.78 ug/mL to 100 ug/mL toward HIV-1, whereas fulvic acids showed much less activity. Time course assays show that humic substances (HS) have antiviral activity at the HIV fusion stage, at the DNA to RNA reverse transcription stage, and at the viral DNA integration stage into the host cell genome. The results of HIV-1 cell binding assay show that all HS blocked HIV-1 cell binding, reducing the number of GFP spots per cell.
Link: https://sci-hub.hkvisa.net/10.1016/j.jaci.2017.12.737
____________________________________________________________
Conclusion: Oxyhumate may prevent HIV infection.
Title: Investigation of the anti-HIV properties of oxyhumate
Document Type: Peer-Reviewed Journal Article
Conclusion: Oxyhumate inhibited HIV-1 infection of MT-2 cells with an IC(50) of 12.5 microg/ml. Treatment of cell-bound and cell-free HIV with oxyhumate irreversibly reduced infectivity, whereas the susceptibility of target cells to virus was not affected by treatment prior to infection. Infectivity of HIV particles was inhibited by interference with CD4 binding and the V3 loop-mediated viral entry step. No viral resistance to oxyhumate developed over a 12-week period in vitro.
____________________________________________________________
Conclusion: Oxyhumate may stimulate the immune system in immunocompromised individuals.
Title: Investigation of the immunostimulant properties of oxyhumate.
Document Type: Peer-Reviewed Journal Article
Conclusion: Oxyhumate increased the proliferative response of phytohemagglutinin-stimulated human lymphocytes, from a concentration of 20 μg/ml onwards. This response was even more striking in the case of lymphocytes from HIV-infected patients and was not limited to the in vitro setting, as similar effects were observed ex vivo following administration of a nontoxic dose of 4 g of oxyhumate daily to HIV-positive individuals for two weeks. Therefore, oxyhumate holds promise for the treatment of immunocompromised patients.
